| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Medical Department II, Laboratory of Endocrine Research, Klinikum Grosshadern (M.M.W., C.F., D.E.); Institute for Animal Pathology (K.M.H.B., P.S.); and Institute for Molecular Animal Breeding/Gene Center (K.G., H.L., E.W.), Ludwig-Maximilian University, Munich 81366, Germany
Address all correspondence and requests for reprints to: Matthias M. Weber, M.D., Medizinische Klinik II, Klinikum Grosshadern, Marchioninistrasse 15, 81377 München, Germany.
The influence of postnatal insulin-like growth factor II (IGF-II) overexpression on adrenal growth and function was investigated in 3-month-old male phosphoenolpyruvate carboxykinase (PEPCK) promoter human IGF-II transgenic mice, which are characterized by 4- to 6-fold elevated postnatal IGF-II serum levels. Plasma corticosterone levels of PEPCK-IGF-II transgenic mice were 2-fold higher than in age- and sex-matched controls, both in the morning (7.4 ± 1.5 vs. 17.8 ± 3.9 ng/ml, P < 0.01) and in the evening (33.3 ± 6.5 vs. 65.3 ± 12 ng/ml, P < 0.01). When PEPCK-IGF-II transgenic mice were subjected to an ACTH challenge, corticosterone levels were stimulated 6-fold, to 396 ± 17 ng/ml after 60 min, compared with 230 ± 24 ng/ml in the control group. In contrast to corticosterone, plasma ACTH levels were similar in transgenic and control mice, excluding an indirect effect of IGF-II at the hypothalamic or pituitary level. In vitro, the basal and ACTH-induced corticosterone production of adrenal glands from transgenic mice was higher (2-fold and 1.8-fold, respectively) than that of control organs. However, when normalized for adrenal weight, the in vitro corticosterone secretion was similar in both groups. At autopsy, adrenal weights of transgenic mice were significantly greater than those of control adrenal glands (3.3 ± 0.2 vs. 2.0 ± 0.2 mg, P < 0.01, n = 10). Furthermore, a local expression of human IGF-II could be demonstrated in transgenic adrenal glands by RT-PCR, whereas in normal adult mice, no adrenal expression of IGF-II was detected. Stereological investigation of adrenal glands from another set of PEPCK-IGF-II transgenic mice and controls (6-month-old males) demonstrated that the increase in adrenal weight in transgenic mice is mainly caused by a 50% increase in the number of zona fasciculata cells, whereas cell volume and zonation of transgenic adrenal glands remained unchanged. In conclusion, our data indicate that postnatal overexpression of IGF-II induces an increased adrenal weight and elevated corticosterone serum levels, presumably by a direct mitogenic effect of IGF-II on adrenocortical fasciculata cells.
This article has been cited by other articles:
![]() |
M. Bielohuby, J. Roemmler, J. Manolopoulou, I. Johnsen, M. Sawitzky, J. Schopohl, M. Reincke, E. Wolf, A. Hoeflich, and M. Bidlingmaier Chronic Growth Hormone Excess Is Associated with Increased Aldosterone: A Study in Patients with Acromegaly and in Growth Hormone Transgenic Mice Experimental Biology and Medicine, August 1, 2009; 234(8): 1002 - 1009. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Kim, F. M. Barlaskar, J. H. Heaton, T. Else, V. R. Kelly, K. T. Krill, J. O. Scheys, D. P. Simon, A. Trovato, W.-H. Yang, et al. In Search of Adrenocortical Stem and Progenitor Cells Endocr. Rev., May 1, 2009; 30(3): 241 - 263. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoeflich and M. Bielohuby Mechanisms of adrenal gland growth: signal integration by extracellular signal regulated kinases1/2 J. Mol. Endocrinol., March 1, 2009; 42(3): 191 - 203. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rodriguez-Galindo, G. Zambetti, and R. C. Ribeiro Epidemiology, Clinical Characteristics, and Treatment of Childhood Adrenocortical Tumors ASCO Educational Book, January 1, 2009; 2009(1): 625 - 629. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Q. Almeida, M. C. B. V. Fragoso, C. F. P. Lotfi, M. G. Santos, M. Y. Nishi, M. H. S. Costa, A. M. Lerario, C. C. Maciel, G. E. Mattos, A. A. L. Jorge, et al. Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3524 - 3531. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. H. Soon, K. L. McDonald, B. G. Robinson, and S. B. Sidhu Molecular Markers and the Pathogenesis of Adrenocortical Cancer Oncologist, May 1, 2008; 13(5): 548 - 561. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Manolopoulou, M Bielohuby, S J Caton, C E Gomez-Sanchez, I Renner-Mueller, E Wolf, U D Lichtenauer, F Beuschlein, A Hoeflich, and M Bidlingmaier A highly sensitive immunofluorometric assay for the measurement of aldosterone in small sample volumes: validation in mouse serum J. Endocrinol., February 1, 2008; 196(2): 215 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bielohuby, N. Herbach, R. Wanke, C. Maser-Gluth, F. Beuschlein, E. Wolf, and A. Hoeflich Growth analysis of the mouse adrenal gland from weaning to adulthood: time- and gender-dependent alterations of cell size and number in the cortical compartment Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E139 - E146. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. West, G. A. Neale, S. Pounds, B. C. Figueredo, C. Rodriguez Galindo, M. A. D. Pianovski, A. G. Oliveira Filho, D. Malkin, E. Lalli, R. Ribeiro, et al. Gene Expression Profiling of Childhood Adrenocortical Tumors Cancer Res., January 15, 2007; 67(2): 600 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Silva, M. Venihaki, W.-H. Guo, and M. F. Lopez Igf2 Deficiency Results in Delayed Lung Development at the End of Gestation Endocrinology, December 1, 2006; 147(12): 5584 - 5591. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zaina, L. Pettersson, A. B. Thomsen, C.-M. Chai, Z. Qi, J. Thyberg, and J. Nilsson Shortened Life Span, Bradycardia, and Hypotension in Mice with Targeted Expression of an Igf2 Transgene in Smooth Muscle Cells Endocrinology, June 1, 2003; 144(6): 2695 - 2703. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. HOEFLICH, M. M. WEBER, T. FISCH, S. NEDBAL, C. FOTTNER, M. W. ELMLINGER, R. WANKE, and E. WOLF Insulin-like growth factor binding protein 2 (IGFBP-2) separates hypertrophic and hyperplastic effects of growth hormone (GH)/IGF-I excess on adrenocortical cells in vivo FASEB J, November 1, 2002; 16(13): 1721 - 1731. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Wilkin, N. Gagné, J. Paquette, L. L. Oligny, and C. Deal Pediatric Adrenocortical Tumors: Molecular Events Leading to Insulin-Like Growth Factor II Gene Overexpression J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2048 - 2056. [Abstract] [Full Text] |
||||
![]() |
A. Hoeflich, O. Fettscher, H. Lahm, W. F. Blum, H. J. Kolb, D. Engelhardt, E. Wolf, and M. M. Weber Overexpression of Insulin-like Growth Factor-binding Protein-2 Results in Increased Tumorigenic Potential in Y-1 Adrenocortical Tumor Cells Cancer Res., February 1, 2000; 60(4): 834 - 838. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |